Details for Patent: 11,850,225

« Back to Dashboard

Which drugs does patent 11,850,225 protect, and when does it expire?

Patent 11,850,225 protects LYVISPAH and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 11,850,225

Title:	Baclofen formulations and methods of minimizing patient exposure to metabolite variations
Abstract:	Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.
Inventor(s):	Leonard O'MAHONY, Sharon Hamm, John Devane, David Penake, Wolfgang Mohr, Manuel Weinheimer
Assignee:	Amneal Pharmaceuticals LLC
Application Number:	US17/861,844
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 11,850,225

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Strides Pharma Intl	LYVISPAH	baclofen	GRANULE;ORAL	215422-001	Nov 22, 2021		DISCN	Yes	No			Y			TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY
Strides Pharma Intl	LYVISPAH	baclofen	GRANULE;ORAL	215422-001	Nov 22, 2021		DISCN	Yes	No			Y			TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES
Strides Pharma Intl	LYVISPAH	baclofen	GRANULE;ORAL	215422-002	Nov 22, 2021		DISCN	Yes	No			Y			TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES
Strides Pharma Intl	LYVISPAH	baclofen	GRANULE;ORAL	215422-002	Nov 22, 2021		DISCN	Yes	No			Y			TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY
Strides Pharma Intl	LYVISPAH	baclofen	GRANULE;ORAL	215422-003	Nov 22, 2021		DISCN	Yes	No			Y			TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES
Strides Pharma Intl	LYVISPAH	baclofen	GRANULE;ORAL	215422-003	Nov 22, 2021		DISCN	Yes	No			Y			TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY

International Family Members for US Patent 11,850,225

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2023055457